Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001214439 | SCV001386121 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-09-10 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 944110). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 1555 of the ATM protein (p.Leu1555Pro). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Baylor Genetics | RCV003469362 | SCV004210115 | uncertain significance | Familial cancer of breast | 2023-07-29 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV004033929 | SCV005017479 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-14 | criteria provided, single submitter | clinical testing | The p.L1555P variant (also known as c.4664T>C), located in coding exon 30 of the ATM gene, results from a T to C substitution at nucleotide position 4664. The leucine at codon 1555 is replaced by proline, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |